Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. Two out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 57 points (-0.3%) at 16,357 as of Wednesday, Jan. 22, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,698 issues advancing vs. 1,213 declining with 185 unchanged. The Drugs industry currently is unchanged today versus the S&P 500, which is down 0.1%. TheStreet would like to highlight 5 stocks pushing the industry lower today: 5. Novartis ( NVS) is one of the companies pushing the Drugs industry lower today. As of noon trading, Novartis is down $0.65 (-0.8%) to $80.72 on average volume. Thus far, 725,877 shares of Novartis exchanged hands as compared to its average daily volume of 1.2 million shares. The stock has ranged in price between $80.66-$80.99 after having opened the day at $80.84 as compared to the previous trading day's close of $81.37. Novartis AG engages in the research, development, manufacture, and marketing of a range of healthcare products worldwide. Novartis has a market cap of $197.7 billion and is part of the health care sector. The company has a P/E ratio of 20.9, above the S&P 500 P/E ratio of 17.7. Shares are up 1.2% year-to-date as of the close of trading on Tuesday. Currently there are 3 analysts that rate Novartis a buy, no analysts rate it a sell, and 3 rate it a hold. TheStreet Ratings rates Novartis as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, reasonable valuation levels, good cash flow from operations, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Novartis Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.